ESR1 and breast carcinoma: Therefore, long-term human studies that monitor free estrogens and their conjugates reported that high-dose genistein and daidzein intake may potentially cause adverse events in patients diagnosed with ERα-positive, and not ERβ-positive, breast cancer [191].